<DOC>
	<DOC>NCT00307515</DOC>
	<brief_summary>A comparison of fibrin sealant 2 versus Surgicel® as an addition to standard surgical practice in stopping mild to moderate soft tissue bleeding during retroperitoneal or intra-abdominal surgery.</brief_summary>
	<brief_title>Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery</brief_title>
	<detailed_description>The time it will take to stop bleeding will be measured and compared between patients who are treated with fibrin sealant 2 to those who are treated with Surgicel®.</detailed_description>
	<mesh_term>Blood Loss, Surgical</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>Male and Female subjects requiring nonemergent retroperitoneal or intraabdominal surgical procedures Presence of an appropriate softtissue target bleeding site (challenging bleeding site for which topical hemostatic adjuncts might typically be used) as identified intraoperatively by the surgeon Subjects must be willing to participate in the study and provide written informed consent Subjects undergoing emergency surgery Parenchymal or anastomotic bleeding sites will not be considered for randomization Subjects with any intraoperative findings identified by the surgeon that may preclude conduct of the study procedure Subjects with known intolerance to blood products or to one for the components of the study product Subjects unwilling to receive blood products Subjects with known autoimmune immunodeficiency diseases (including known HIV Subjects who are known, current alcohol and/or drug abusers Subjects who have participated in another investigational drug or device research study within 30 days of enrollment Female subjects who are pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>